A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment -Naive Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) while Receiving Telaprevir, Peginterferon Alfa2a (Pegasys) and Ribavirin (Copegus) [VX08-950-111]

ID Number 08-0928

Principal Investigator(s)
Douglas Dieterich

Department(s) or Division(s)
Liver Diseases

Description

The purpose of this study is to learn more about the safety and effectiveness of the study drug, called telaprevir, when it is combined with peginterferon a-2a (Pegasys®) and ribavirin (Copegus®) and given to patients with hepatitis C virus (HCV) who have never been treated for their HCV.



Contact Information
Douglas Dieterich, MD
douglas.dieterich@mountsinai.org

Recruiting Patients: No